Monitor the pace of actual ATM sales to gauge dilution and management's capital needs. If the stock price weakens, dilution will be immediate. Watch for any subsequent 8-K reporting quarterly sales amounts to track. No earnings or guidance from the next 10-Q for revenue.
Price Chart
Executive Summary
CalciMedica filed a 424B5 prospectus supplement to sell up to $25 million of common stock via an at-the-market (ATM) offering through H.C. Wainwright & Co. The ATM allows the clinical-stage biopharma to raise capital at prevailing market prices, with a 3.0% commission to Wainwright. Proceeds are for general corporate purposes, including R&D and clinical trials. The filing signals ongoing cash needs and potential dilution for existing shareholders.
Key Facts
- Up to $25,000,000 of common stock offered via ATM through H.C. Wainwright & Co.
- Last reported sale price on Sept 28, 2026: $1.695 per share.
- Wainwright receives 3.0% commission on gross sales proceeds.
- Proceeds for general corporate purposes including R&D, clinical trials, working capital.
- As of June 30, 2026, net tangible book value was ~$5.5M ($0.90/share pre-offering); after full sale at $1.695/share, dilution per new investor is $0.285/share.
- Company is a clinical-stage biopharma with no approved products; prior financials not provided in filing.
- Reverse stock split 1-for-5 effective Aug 28, 2026.
- Audited financials include a going concern uncertainty paragraph in the auditor's report.
Financial Impact
Up to $25M gross proceeds; net proceeds not determinable; dilution of $0.285 per share for new investors assuming full $25M sale at $1.695/share.
Risk Factors
- Immediate dilution from ATM; no minimum offering amount not required.
- No guarantee any shares sold; proceeds may not yield return.
- Further dilution from existing warrants/options exercise.
- Clinical-stage; no approved products; high risk of failure.
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-409041 |
| Document: 0001193125-26-409041-index-headers.html | 0001193125-26-409041 |
| Document: 0001193125-26-409041-index.html | 0001193125-26-409041 |
| Document: 0001193125-26-409041.txt | 0001193125-26-409041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 8-K | $1.02 | awaiting T+20 | — | $1.30 (−27.45%) |
Sep 30, 2026 26d ago | 8-K | $1.65 | awaiting T+20 | — | $1.30 (+21.21%) |
Sep 30, 2026 26d ago | 424B5 | $1.65 | awaiting T+20 | — | $1.30 (+21.21%) |
Sep 2, 2026 7w ago | 8-K | $2.10 $1.65 | ▲ +21.43% | ▲ +21.28% | $1.30 (+38.10%) |
Aug 11, 2026 10w ago | 8-K | $0.6577 $0.4590 | ▲ +30.21% | ▲ +29.15% | $1.30 (−97.66%) |
Aug 11, 2026 10w ago | Press Release | $0.6577 $0.4590 | ▼ −30.21% | ▼ −29.15% | $1.30 (+97.66%) |
Jul 10, 2026 15w ago | 3 | $0.8178 $0.6590 | ▼ −19.42% | ▼ −22.60% | $1.30 (+58.96%) |
Jun 24, 2026 17w ago | 8-K | $0.5973 $0.7159 | ▼ −19.86% | ▼ −19.18% | $1.30 (−117.65%) |
May 12, 2026 23w ago | 8-K | $0.6300 $0.9320 | ▲ +47.94% | ▲ +49.66% | $1.30 (+106.35%) |
Mar 12, 2026 32w ago | EFFECT | $0.7260 $0.6180 | ▼ −14.88% | ▼ −16.85% | $1.30 (+79.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers